Document ID: chunk:federal_register_of_legislation:F2024L00752:reg:9:p2
Version: federal_register_of_legislation:F2024L00752
Segment Type: reg
Provision Reference: reg 9 (pt 2/2)
Character Range: 7070–9220

hepatic arterial infusion; or
(c)          potassium chloride tablet (enteric coated or wax formulation);
(14)      being treated with one of the following drugs or class of drugs for at least 2 weeks, within the 3 months before clinical onset;
(a)          clopidogrel;
(b)          glucocorticoid, excluding topical or inhaled;
(c)          deferasirox;
(d)          nicorandil;
(e)          paracetamol of more than 2 grams daily; or
(f)           selective serotonin re-uptake inhibitors;
(15)      taking one of the following drugs or class of drugs for at least 2 weeks, within the 3 months before clinical worsening;
(a)          anticoagulants;
(b)          clopidogrel;
(c)          corticosteroids, excluding topical or inhaled;
(d)          lanthanum;
(e)          levodopa with benserazide or carbidopa;
(f)           methylnaltrexone;
(g)          nicotinic acid;
(h)          paracetamol of more than 2 grams daily;
(i)            pentoxifylline;
(j)            selective serotonin re-uptake inhibitors;
(k)          spironolactone;
(l)            tocilizumab;
(m)         tofacitinib; or
(n)          upadacitinib;
(16)      having cirrhosis of the liver at the time of clinical onset or clinical worsening;
(17)      having alcohol use disorder or drinking at least 4 standard drinks per day for at least 6 months at the time of bleeding of a duodenal ulcer;
Note 1: The bleeding of a duodenal ulcer is considered to be a clinical worsening.
Note 2: Alcohol consumption is calculated utilising the Australian Standard of 10 grams of alcohol per standard alcoholic drink.
(18)      having Crohn disease (a type of inflammatory bowel disease) at the time of clinical onset or clinical worsening;
(19)      having one of the following medical conditions at the time of clinical onset or clinical worsening;
(a)          amyloidosis;
(b)          eosinophilic gastroenteritis;
(c)          sarcoidosis;
(d)          systemic mastocytosis;
Note: systemic mastocytosis is defined in the Schedule 1 – Dictionary.
(20)      inability to obtain appropriate clinical management for duodenal ulcer and duodenal erosion before clinical worsening.